AIMS: We assessed the lower urinary tract symptoms (LUTS) of patients with Parkinson's disease (PD) and their association with different clinical parameters. METHODS: We prospectively evaluated 110 patients (84 men), with a mean age of 61.8 +/- 9.6 years. Mean duration of the disease was 12.3 +/- 7.2 years. Neurological impairment was assessed by the Hoehn-Yahr and the Unified Parkinson Disease Rating scales. LUTS were assessed by the International Continence Society questionnaire. We evaluated the impact of age, PD duration, neurological impairment, gender, and use of anti-Parkinsonian drugs on the voiding function. RESULTS: On multivariate analysis, voiding dysfunction increased with the neurological impairment, but not with patient's age or disease duration. Quality of life (QOL) was affected by the severity of LUTS, and the symptoms with the worst impact were frequency and nocturia. Sixty-three (57.2%) patients were symptomatic. They did not differ with the asymptomatic as to age and disease duration, but had more severe neurological impairment. No impact on LUTS was associated with the use of levodopa, anticholinergics, and dopamine receptor agonists. Men and women were similarly affected by urinary symptoms. CONCLUSIONS: The severity of the neurological disease is the only predictive factor for the occurrence of voiding dysfunction, which affects men and women alike. (c) 2009 Wiley-Liss, Inc.
AIMS: We assessed the lower urinary tract symptoms (LUTS) of patients with Parkinson's disease (PD) and their association with different clinical parameters. METHODS: We prospectively evaluated 110 patients (84 men), with a mean age of 61.8 +/- 9.6 years. Mean duration of the disease was 12.3 +/- 7.2 years. Neurological impairment was assessed by the Hoehn-Yahr and the Unified Parkinson Disease Rating scales. LUTS were assessed by the International Continence Society questionnaire. We evaluated the impact of age, PD duration, neurological impairment, gender, and use of anti-Parkinsonian drugs on the voiding function. RESULTS: On multivariate analysis, voiding dysfunction increased with the neurological impairment, but not with patient's age or disease duration. Quality of life (QOL) was affected by the severity of LUTS, and the symptoms with the worst impact were frequency and nocturia. Sixty-three (57.2%) patients were symptomatic. They did not differ with the asymptomatic as to age and disease duration, but had more severe neurological impairment. No impact on LUTS was associated with the use of levodopa, anticholinergics, and dopamine receptor agonists. Men and women were similarly affected by urinary symptoms. CONCLUSIONS: The severity of the neurological disease is the only predictive factor for the occurrence of voiding dysfunction, which affects men and women alike. (c) 2009 Wiley-Liss, Inc.
Authors: Susan A Hall; Teresa M Curto; Ahunna Onyenwenyi; Gary E Lemack; Sharon L Tennstedt; Carol L Link; John B McKinlay Journal: Neurourol Urodyn Date: 2012-06-06 Impact factor: 2.696
Authors: Anne Pavy-Le Traon; Nikki Cotterill; Gerard Amarenco; Susanne Duerr; Horacio Kaufmann; Heinz Lahrmann; François Tison; Gregor K Wenning; Christopher G Goetz; Werner Poewe; Cristina Sampaio; Anette Schrag; Olivier Rascol; Pablo Martinez-Martin; Glenn T Stebbins Journal: Mov Disord Clin Pract Date: 2018-10-25
Authors: Cristiano M Gomes; Zein M Sammour; Jose de Bessa Junior; Egberto R Barbosa; Roberto I Lopes; Flávio S Sallem; Flavio E Trigo-Rocha; Homero Bruschini; Victor W Nitti; Miguel Srougi Journal: Clinics (Sao Paulo) Date: 2014 Impact factor: 2.365
Authors: André Luiz Farinhas Tomé; Eduardo P Miranda; José de Bessa Júnior; Carlos Alberto Bezerra; Antônio Carlos Lima Pompeo; Sidney Glina; Cristiano Mendes Gomes Journal: Clinics (Sao Paulo) Date: 2019-03-14 Impact factor: 2.365